Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2019.01.14
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 L ...
PDF (265 KB)
2019.01.29
Carrie Ann Inaba Partners with Daiichi Sankyo, Inc. to Encourage Americans to “Get Iron Informed”
PDF (474 KB)
2019.02.05
FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartin ...
PDF (190 KB)
2019.02.22
Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company’s Launch into its Next Growth Ph ...
PDF (179 KB)
2019.03.28
Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for ...
PDF (188 KB)
2019.03.28
Daiichi Sankyo Confirms Plans to Accelerate BLA Submission to U.S. FDA for [Fam-] Trastuzumab Derux ...
PDF (192 KB)
2019.04.03
EMA Validates Daiichi Sankyo’s Marketing Authorization Application for Pexidartinib for Treatment o ...
PDF (353 KB)
2019.04.04
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with ...
PDF (168 KB)
2019.04.09
Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Tre ...
PDF (186 KB)
2019.04.25
Daiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric™ Bispecific Platform
PDF (428 KB)
Showing 1 - 10 of 34 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...